Ortho Clinical Diagnostics has received a CE mark for its new multitest platform that allows laboratories to run two in vitro diagnostic tests simultaneously on one slide.
The company’s Vitros XT MicroSlide employs digital optics to increase productivity while requiring less blood be taken from patients, which Ortho described as important for vulnerable patients and those with venous access issues.
The individual, dual-test slides include paired assays for blood urea nitrogen and creatinine ratios; triglycerides and cholesterol; and glucose and calcium levels, all for use on the Vitros XT 7600 Integrated System. The platform is currently under review by the FDA.
In a statement, Ortho said the system can improve turnaround time, and simplify inventory management and storage space.
RELATED: FDA approves Ortho’s next-generation Vitros HIV combo test
Late last year, the FDA approved Ortho’s HIV combination diagnostic—which detects both HIV-1 and HIV-2 antibodies, as well as the p24 antigen—for use on the Vitros 5600 system. The company described the combination test as being able to detect HIV-1 infections earlier than previous generations of the diagnostic.